收藏 分享(赏)

雾化吸入抗生素治疗呼吸机相关感染_PPT课件.pptx

上传人:微传9988 文档编号:2681039 上传时间:2018-09-25 格式:PPTX 页数:18 大小:1.24MB
下载 相关 举报
雾化吸入抗生素治疗呼吸机相关感染_PPT课件.pptx_第1页
第1页 / 共18页
雾化吸入抗生素治疗呼吸机相关感染_PPT课件.pptx_第2页
第2页 / 共18页
雾化吸入抗生素治疗呼吸机相关感染_PPT课件.pptx_第3页
第3页 / 共18页
雾化吸入抗生素治疗呼吸机相关感染_PPT课件.pptx_第4页
第4页 / 共18页
雾化吸入抗生素治疗呼吸机相关感染_PPT课件.pptx_第5页
第5页 / 共18页
点击查看更多>>
资源描述

1、Ventilator-associated infection: the role for inhaled antibiotics,Lucy B. Palmer Current opinion in pulmonary medicine 2015, 21:239249,Introduction Pathophysiology and rationale Clinical trials Drug resistance Conclusion,outline,Ventilator-associated pneumonia (VAP)Ventilator-associated tracheobronc

2、hitis (VAT) multidrug resistant (MDR) extensively drug-resistant (XDR) inhaled antibiotics nebulizers,Introduction,Subglottic secretions,disturbed mucociliary clearance,damaged mucosa, bacterial biofilm.,Pathophysiology and rationale,Pathophysiology and rationale,Clinical trials,7.8.9.10.,Clinical t

3、rials,11.12.,多研究VAP,1提及VAT,2、12VAT,同一作者。细菌鲍曼不动、铜绿假单胞、肺炎克雷伯多见。抗生素粘菌素多见,万古、庆大、阿米卡星+头孢他啶、妥布等。雾化器多样,部分未描述雾化器。雾化吸入多联合静脉用药。 多未见副作用,6提及低氧血症、滤器堵塞、心脏骤停? 结论:雾化吸入无耐药、缩短全身抗生素使用时间、减少抗生素使用量。细菌根除率高?临床治愈率高?存活率高?,Peak antibiotic concentrations 200-fold (AA+i.v.) Vs (placebo+i.v.):signs of respiratory infectionextuba

4、ted more often need of additional antibiotics bacterial resistance VAT VAP,VAT Clinical trials,X,VAT Clinical trials,Clinical Pulmonary Infection Score volume of secretions(ml/4h) AA:eradicationdrug-resistance,Colistin neurological and renal toxicity stop for 40 years drug-resistance AA,Colistin Cli

5、nical trials,Colistin Clinical trials,7.AA+i.v.: more MDROs (52.6 vs. 14.9%) , higher APACHE II scores (21.45.7 vs. 17.55.3), But Survive more.,8.Lu et al.,AA/(AA+i.v. 3 days) to resistant vs. i.v. to susceptible organisms: cure rate/mortality no difference.AA+i.v. better? 11. Tumbarello et al.,AA+i

6、.v. vs. i.v. to COS:cure rate (69.2 vs. 54.8%) ,mechanical ventilation (8 vs. 12 days),Eradication (63.4 vs. 50%, p=0.08), mortality, ICU stay, AKI: No differences.,Colistin Clinical trials,10.Doshi et al.,AA+i.v. vs. i.v. to MDROs: Cure rate(54.5 vs. 39.2%;p=0.135) , Eradication(44.4 vs. 40.7%;p=0.

7、805), Motality(40 vs. 70%;p=0.055), High quality culture subgroup cure rate (57.1 vs. 31.3%;p=0.033).,Colistin Clinical trials,3. AA+i.v.: no new resistance, 1. AA/AA+i.v.: no new resistance, 2.AA/AA+i.v. vs. placebo+i.v.: 0 vs.33%, 6. AA vs. i.v.: 0 vs. 45%, 12. AA+i.v. vs. placebo+i.v.: 0 vs. 56%,

8、 8.AA/AA+i.v. to resistant vs. i.v. to susceptible organisms :25% susceptible vs.75% resistant. Hypothesis:AA very high antibiotic concentration eradicate the highly resistant organismsdrug-resistance,Drug resistance,The concentrations of antibiotics needed? The best delivery devices ? Systemic antibiotic use ? Drug resistance consistently?,Conclusion/Question,Thanks,

展开阅读全文
相关资源
猜你喜欢
相关搜索

当前位置:首页 > 医学治疗 > 临床医学

本站链接:文库   一言   我酷   合作


客服QQ:2549714901微博号:道客多多官方知乎号:道客多多

经营许可证编号: 粤ICP备2021046453号世界地图

道客多多©版权所有2020-2025营业执照举报